[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. El Sharouni SY, Aerts JG, Senan S, De Ruysscher DK, Groen HJ, Paul MA, Smit EF, Vonk EJ, Verhagen AF, Schramel FM: [Treatment of patients with stage III non-small cell lung cancer: concurrent high-dose chemotherapy and radiotherapy]. Ned Tijdschr Geneeskd; 2008 Dec 13;152(50):2714-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of patients with stage III non-small cell lung cancer: concurrent high-dose chemotherapy and radiotherapy].
  • [Transliterated title] Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III: gelijktijdig hooggedoseerde chemotherapie en radiotherapie.
  • The treatment of patients with locally advanced non-small cell lung cancer (stage III) has changed significantly in the past few years.
  • Patients with a non-resectable stage IIIA/B tumour are given combined treatment consisting ofchemotherapy and radiotherapy.
  • Cisplatin and etoposide are usually the drugs of choice for chemotherapy in patients with stage III cancer.
  • A biologically effective dose of radiotherapy equivalent to 60-66 Gy, over a maximum of 6.5 weeks, should be given.
  • It is recommended to apply this treatment in a research setting.
  • High-dose concurrent chemoradiotherapy is advised as the standard treatment for stage III non-small cell lung cancer in patients in good physical condition.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Combined Modality Therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Drug Administration Schedule. Humans. Neoplasm Staging. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2008 Dec 13;152(50):2709-13 [19192583.001]
  • (PMID = 19192584.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 20
  •  go-up   go-down


2. Uitterhoeve AL, Belderbos JS, van Zandwijk N, Koning CC: [Perspectives in the treatment of non-small cell lung cancer stage III with radiotherapy and concomitant low-dosage chemotherapy]. Ned Tijdschr Geneeskd; 2008 Dec 13;152(50):2709-13
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Perspectives in the treatment of non-small cell lung cancer stage III with radiotherapy and concomitant low-dosage chemotherapy].
  • [Transliterated title] Perspectieven in de behandeling van het niet-kleincellige longcarcinoom stadium III met radiotherapie en gelijktijdig gegeven laaggedoseerde chemotherapie.
  • Patients with a non-small cell lung cancer stage III should preferably be treated with a combination of concomitant radiotherapy and platinum-containing chemotherapy.
  • Concomitant chemoradiation results in improved survival compared to sequential chemoradiation, although this type oftreatment is associated with higher oesophagus toxicity.
  • With concomitant chemoradiation the chemotherapy can be added in several ways to high-dosage radiotherapy, for example in the form of 2 courses of high dose, platinum-containing polychemotherapy once every 3 weeks.
  • In view of its low risk of haematological and renal toxicity and ototoxicity and smaller cardiac load this is the therapy of choice and is also highly suitable for elderly patients with comorbidity.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Combined Modality Therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Dose-Response Relationship, Drug. Drug Administration Schedule. Humans. Neoplasm Staging. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ned Tijdschr Geneeskd. 2008 Dec 13;152(50):2714-7 [19192584.001]
  • (PMID = 19192583.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Comment; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 28
  •  go-up   go-down


3. Wolf R, Barzilai A, Davidovici B: Intertriginous lymphomatoid drug eruption. Int J Dermatol; 2010 Oct;49(10):1207-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intertriginous lymphomatoid drug eruption.
  • A 76-year-old man developed a maculopapular purpuric eruption confined to the intertriginous areas (i.e. the inguinal, gluteal, and axillary folds).
  • Two days before the eruption appeared, he had received a second course of chemotherapy consisting of cisplatinum 40 mg and gemcitabine (Gemzar) 1700 mg for the treatment of squamous cell carcinoma of the lung stage III B.
  • The histologic picture was of either lymphomatoid drug eruption or lymphomatoid papulosis.
  • The antineoplastic therapy was changed to once-weekly intravenous vinorelbine (Navelbine) 50 mg, a Vinca alkaloid, and the eruption resolved completely within two weeks without any further therapy.
  • These circumstantial evidences support the diagnosis of intertriginous drug eruption.
  • Our case is interesting and unusual in that it demonstrated a rare clinical presentation of drug eruption, namely, intertriginous drug eruption or baboon syndrome, with a histologic picture of a lymphomatoid drug eruption that can mimic lymphoma.
  • We are unaware of any earlier reported case of baboon syndrome with a histologic picture of lymphomatoid drug eruption.
  • The pathomechanisms of both types of drug eruption, i.e. baboon syndrome and lymphomatoid drug eruption, are not fully understood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cisplatin / adverse effects. Deoxycytidine / analogs & derivatives. Intertrigo / chemically induced
  • [MeSH-minor] Aged. Humans. Lung Neoplasms / drug therapy. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 The International Society of Dermatology.
  • (PMID = 20883412.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Marucci G, Sgarbanti E, Maestri A, Calandri C, Collina G: Gemcitabine-associated CD8+ CD30+ pseudolymphoma. Br J Dermatol; 2001 Oct;145(4):650-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a 69-year-old man with a non-small cell carcinoma of the lung, stage III B, who developed bilateral multiple erythematous lesions in the abdominal-inguinal area following treatment with gemcitabine.
  • Although rarely reported, gemcitabine therapy can induce skin lesions.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Pseudolymphoma / chemically induced

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11703296.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, CD8; 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


5. Shabnam MS, Srinivasan R, Wali A, Majumdar S, Joshi K, Behera D: Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung. Lung Cancer; 2004 Aug;45(2):181-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung.
  • This pathway may be dysregulated leading to an altered ratio of pro- and anti-apoptotic molecules, hence rendering cells resistant to chemotherapy.
  • The objective of this study was to understand the role of Bcl-2 family members in mediation of apoptosis in squamous cell carcinoma of the lung.
  • RESULTS: Bronchoscopically obtained lung biopsies from 30 cases of histologically proven squamous cell carcinoma of the lung in stage III were assessed for the expression of Bcl-2, Bcl-XL, and Bax at the mRNA and protein levels by semi-quantitative reverse transcription (RT-PCR) and immunohistochemistry.
  • The AI ranged from <0.1 to 6.0% with a median of 1.3%.
  • CONCLUSION: The results of this study indicate that in locally advanced squamous cell carcinoma of the lung, Bax protein is up regulated and determines the level of apoptosis.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15246189.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein
  •  go-up   go-down






Advertisement